GSK656: Clinical Trials

4 completed, 3 recruiting. 4 Phase 2, 3 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	4	Completed 2, Recruiting 2
Phase 1	3	Completed 2, Recruiting 1

Follow GSK656: new trials by email Literature Review of GSK656 trials Research Report on GSK656

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential Ganfeborole, Microgynon - Tuberculosis	Phase 1	Recruiting	GlaxoSmithKline	28	2026-08-20	2026-10-02
A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age Microgynon, GSK3036656 - Tuberculosis	Phase 1	Completed	GlaxoSmithKline	20	2024-04-05	2025-08-26
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis	Phase 2	Recruiting	University College, London	2500	2024-01-09	2026-10-15
PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis	Phase 2	Recruiting	Michael Hoelscher	390	2023-04-14	2025-10-07
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis GSK3036656, Bedaquiline, Delamanid - Tuberculosis	Phase 2	Completed	GlaxoSmithKline	127	2022-07-26	2026-06-17
An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis GSK3036656, Rifafour e-275 - Tuberculosis	Phase 2	Completed	GlaxoSmithKline	76	2019-03-22	2023-10-26
First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects GSK3036656, Placebo - Tuberculosis	Phase 1	Completed	GlaxoSmithKline	30	2017-04-02	2019-04-19

Conditions studied

Tuberculosis (6)  ·  Tuberculosis, Pulmonary (4)

Sponsors

GlaxoSmithKline (5)  ·  Michael Hoelscher (1)  ·  University College, London (1)

Countries

South Africa (4)  ·  Spain (2)  ·  Tanzania (2)  ·  Uganda (2)  ·  Gabon (1)  ·  Malawi (1)  ·  Moldova (1)  ·  Mozambique (1)  ·  United Kingdom (1)  ·  Vietnam (1)

Top investigators

Michael Hoelscher, Prof Dr. (1)

Results publications

PMID 31182528, PMID 35876255, PMID 38365949

NIH funding

2015 (1)